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This editorial refers to ‘The consistency of the treatment
effect of an ACE inhibitor-based treatment regimen in
patients with vascular disease or high risk of vascular
disease: a combined analysis of individual data of
ADVANCE, EUROPA, and PROGRESS trials’†, by
J.J. Brugts et al., on page 1385
Angiotensin-converting enzyme inhibitors (ACEIs) have a beneficial
effect on oxidative stress, endothelial function, vascular remodelling,
and the progression of atherosclerosis in animal experiments inde-
pendent of their effect on reducing blood pressure. ACEIs have
also been shown to decrease cardiovascular mortality and morbidity
in patients with vascular disease.1,2 While these results have been
adopted into guidelines, there have been doubts as to whether or
not these benefits were due to a reduction in blood pressure and
therefore possibly any anti-hypertensive strategy might be equally
effective or whether they have an effect independent of blood
pressure lowering. The answer to this question has important impli-
cations. For example, the COURAGE trial3 suggested that optimum
medical therapy, including an ACEI, was as effective in preventing
cardiovascular events in patients with mild to moderate coronary
artery disease as percutaneous coronary angioplasty. The use of
ACEIs in patients with coronary artery disease without other clinical
indications for their use such as hypertension and/or diabetes melli-
tus, however, remains suboptimal.
Brugts et al.4 have analysed the effect of an ACEI-based regimen
using individual patient data from across a wide spectrum of vascu-
lar diseases from the ADVANCE, EUROPA, and PROGRESS
trials2,5,6 which used a perindopril-based regimen that could
include the diuretic indapamide. An analysis from these trials invol-
ving .29 000 patients showed that the perindopril-based regimen
was associated with a significant reduction in all-cause mortality, a
reduction in cardiovascular mortality, as well as a reduction in non-
fatal myocardial infarction, stroke, and heart failure. Of importance
was the finding that these results were consistent in subgroups
with different clinical characteristics and across all strata of baseline
blood pressure and levels of obtained blood pressure (interaction
P-value non-significant).
While the perindopril-based regimen in these trials included inda-
pamide in many patients, the authors separately analysed the data
with perindopril alone in 15 000 individual patients, mainly from
EUROPA2 and part of PROGRESS.6 Although in this analysis the
results for all-cause mortality and cardiovascular mortality alone
were no longer significant, the combination of cardiovascular mor-
tality, non-fatal myocardial infarction, and heart failure were signifi-
cant, but not stroke, which appeared in large part to depend
upon the use of indapamide and a greater degree of blood pressure
lowering. These results reinforce the use of ACEIs in patients with
vascular disease, especially coronary artery disease.
These results also raise several additional questions such as
whether or not they apply to all ACEIs or only to perindopril.
This question must, however, remain unanswered since we do
not have adequately powered prospective comparative trials.
While the possibility of a ‘class effect’ exists, there is a risk in
this assumption, that in my opinion is unwarranted. It would be
prudent to limit the use of ACEIs in patients with vascular
disease without manifest hypertension to those shown to be
effective in reducing cardiovascular events in patients with vascu-
lar disease, such as ramipril at its target dose. Also of importance
is the question as to whether or not an angiotensin receptor
blocker (ARB) could be substituted for an ACEI since ACEIs
have been postulated to have a cardioprotective effect in contrast
to an ARB due to the accumulation of bradykinin. The results of
ONTARGET7 would suggest, however, that the ARB telmesartan
was as effective as the ACEI ramipril in reducing cardiovascular
events in patients with vascular disease. However, while one
would be comfortable in using telmesartan at its target dose in
a patient who did not tolerate an ACEI it should be pointed
out that although there was no significant difference in cardiovas-
cular outcomes between ramipril and telmesartan over the
course of the trial the natural history of vascular disease is far
longer. The recent finding that bradykinin is important for
homing of endothelial progenitor cells and endothelial repair,8
along with the long experience and low cost of ACEIs, would
favour preferential use of an ACEI over an ARB in patients
with vascular disease.
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Since ACEIs appear to be beneficial in improving cardiovascular
outcomes in patients with vascular disease one might also ask
whether or not further blockade of the renin–angiotensin– ldos-
terone system (RAAS) might be even more effective. The results
of ONTARGET7 suggest that there is little to be gained by
adding an ARB to an ACEI, and possibly an increase in the risk
of renal dysfunction.9 The finding that direct renin inhibitors
(DRIs) improve renal blood flow significantly more than an
ACEI10 raises the possibility that adding a DRI to an ACEI might
result in a lower risk of renal dysfunction than when adding an
ARB. However, until further large-scale prospective randomized
trials are available demonstrating the safety and efficacy of this
strategy, one should be cautious about adding a DRI to an ACEI
in patients with vascular disease without manifest hypertension.
There might also be a reason to consider adding an aldosterone
blocker to an ACEI in a patient with vascular disease without mani-
fest hypertension since animal experiments show an added benefit
on the development of atherosclerosis when both an ACEI and an
aldosterone blocker are used.11 However, until these results are
duplicated in adequately powered prospective clinical trials, this
strategy can also not be recommended.
Thus, while there may be other means of blocking the RAAS in
the future, the data of Brugts et al.4 are important today in guiding
the therapy of patients with vascular disease and should encourage
greater use of proven ACEIs at their target doses in patients with
vascular disease independent of the occurrence of hypertension.
Conflict of interest: B.P. is a consultant for Pfizer, Merck,
Novartis, Astra Zeneca, Schering Plough, Bayer, Takeda, and
Bohringer Ingelheim.
References
1. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an
angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in
high-risk patients. The Heart Outcomes Prevention Evaluation Study Investi-
gators. N Engl J Med 2000;342:145–153.
2. Fox K; EURopean trial On reduction of cardiac events with Perindopril in stable
coronary Artery disease Investigators. Efficacy of perindopril in reduction of car-
diovascular events among patients with stable coronary artery disease: random-
ised, double-blind, placebo-controlled, multicentre trial (the EUROPA study).
Lancet 2003;362:782–788.
3. Boden WE, O’Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ,
Knudtson M, Dada M, Casperson P, Harris CL, Chaitman BR, Shaw L,
Gosselin G, Nawaz S, Title LM, Gau G, Blaustein AS, Booth DC, Bates ER,
Spertus JA, Berman DS, Mancini GB, Weintraub WS. Optimal medical therapy
with or without PCI for stable coronary disease. N Engl J Med 2007;356:
1503–1516.
4. Brugts JJ, Ninomiya T, Boersma E, Remme WJ, Bertrand M, Ferrari R, Fox K,
MacMahon S, Chalmers J, Simoon ML. The consistency of the treatment
effect of an ACE inhibitor-based treatment regimen in patients with
vascular disease or high risk of vascular disease: a combined analysis of
individual data of ADVANCE, EUROPA, and PROGRESS trials. Eur Heart J
2009;30:1385–1394. First published on 4 April 2009. doi:10.1093/eurheartj/
ehp103.
5. Patel A, MacMahon S, Chalmers J, Neal B, Woodward M, Billot L, Harrap S,
Poulter N, Marre M, Cooper M, Glasziou P, Grobbee DE, Hamet P
Heller S, Liu LS, Mancia G, Mogensen CE, Pan CY, Rodgers A, Williams B.
Effects of a fixed combination of perindopril and indapamide on
macrovascular and microvascular outcomes in patients with type 2 diabetes
mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007;370:
829–840.
6. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-
pressure lowering regimen among 6,105 individuals with previous stroke of tran-
sient ischaemic attack. Lancet 2001;358:1033–1041.
7. ONTARGET investigators, Yusuf S, Teo KK, Pogue J, Dyal L, Copland I,
Schumacher H, Dagenais G, Sleight P, Anderson C. Telmisartan, ramipril, or
both in patients at high risk for vascular events. N Engl J Med 2008;358:
1547–1559.
8. Krankel N, Katare RG, Siragusa M, Barcelos LS, Campagnolo P, Mangialardi G,
Fortunato O, Spinetti G, Tran N, Zacharowski K, Wojakowski W, Mroz I,
Herman A, Manning Fox JE, MacDonald PE, Schanstra JP, Bascands JL,
Ascione R, Angelini G, Emanueli C, Madeddu P. Role of kinin B2 receptor signaling
in the recruitment of circulating progenitor cells with neovascularization poten-
tial. Circ Res 2008;103:1335–1343.
9. Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, Wang X,
Maggioni A, Budaj A, Chaithiraphan S, Dickstein K, Keltai M, Metsarinne K,
Oto A, Parkhomenko A, Piegas LS, Svendsen TL, Teo KK, Yusuf S. Renal out-
comes with telmisartan, ramipril, or both, in people at high vascular risk (the
Editorial1308
 at Erasm
us University Rotterdam
 on August 1, 2011
e
u
rheartj.oxfordjournals.org
D
ow
nloaded from
 
ONTARGET study): a multicentre, randomised, double-blind, controlled trial.
Lancet 2008;372:547–553.
10. Fisher ND, Hollenberg NK. Renin inhibition: what are the therapeutic opportu-
nities? J Am Soc Nephrol 2005;16:592–599.
11. Imanishi T, Tsujioka H, Ikejima H, Kuroi A, Takarada S, Kitabata H, Tanimoto T,
Muragaki Y, Mochizuki S, Goto M, Yoshida K, Akasaka T. Renin inhibitor aliskiren
improves impaired nitric oxide bioavailability and protects against atherosclerotic
changes. Hypertension 2008;52:563–572.
CARDIOVASCULAR FLASHLIGHT
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
doi:10.1093/eurheartj/ehp017
Online publish-ahead-of-print 24 February 2009
Three aneurysms developed in three different drug-eluting stents
Young-Soo Lee*, Kee-Sik Kim, and Sung-Gug Chang
Division of Cardiology, College of Medicine, Daegu Catholic University Medical Center, 3056-6, Daemyung-4-dong, Nam-gu, Daegu, Republic of Korea
* Corresponding author. Tel: þ82 53 650 3041, Fax: þ82 53 621 3166. Email: mdleeys@cu.ac.kr
A 42-year-old man presented with
chest angina. He had exertion
chest discomfort 1 month ago. He
had no cardiovascular risk factors.
Chest X-ray revealed no cardio-
megaly. Electrocardiogram revealed
ST-segment elevation in lead II, III,
and aVF. Echocardiography showed
hypokinesia in inferior wall with an
ejection fraction of 45%. We diag-
nosed ST-elevation myocardial infarc-
tion in inferior wall. We performed a
coronary angiography (CAG) for
primary percutaneous coronary inter-
vention. The CAG showed a signifi-
cant stenosis with plaque rupture at
bifurcation portion of postero-lateral
branch and postero-descending
branch of the right coronary artery
(RCA), which is considered as
infarct-related artery, and a significant
stenosis at proximal portion of the left
anterior descending artery (LAD) and
the left circumflex artery (LCX).
The RCA lesion was pre-dilated
and implanted (zotarolimus-eluting
stent 3.5  24 mm). After 3 days,
we implanted two different stents
at two significant lesions of LAD
and LCX (LAD: sirolimus-eluting stent 3.5  23 mm; LCX: paclitaxel-eluting stent 3.5  24 mm) because of product delivery
(Panels A, B, and C ). We treated with aspirin 100 mg/day and clopidogrel 75 mg/day.
Six months later, he was admitted at our hospital due to atypical chest pain. We performed CAG. Follow-up CAG revealed huge
aneurysms around the stents in RCA and LCX and small aneurysm around the stent in LAD (Panels D, E, and F ). The aneurysms were
clearly visible on intravascular ultrasound (Panels G, H, and I). We decided to treat with medication of three anti-platelet agents
(aspirin, clopidogrel, and cilostazol) without additional intervention. He has been free of symptom until now.
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